HIV / AIDS

Colleen Kelley, MD, stresses the importance of routinizing HIV testing and shares what physicians can do if their patient declines the option to get tested.

A recent study finds that daily antituberculosis therapy is more effective than a thrice-weekly regimen among HIV-positive patients with pulmonary tuberculosis.

A new study finds that a 1-month course of antibiotics is as safe & effective as the commonly recommended 9-month course in preventing tuberculosis in those with HIV.

A new study suggests that an antiretroviral combination of dolutegravir with darunavir/cobicistat can be prescribed safely in the treatment of HIV-1.

AIDS researcher Robert Redfield, MD, has officially been named the new director of the CDC.

Joseph Eron, MD, discusses when clinicians may expect to have access to long-acting injectable ART and the different opportunities it offers for individuals with HIV.

Implementation of a rapid entry program decreased time to first provider appointment, time to initiation of ART, and time to viral suppression in the Southern United States.

Colleen Kelley, MD, explains what is needed to ensure that individuals get tested for HIV.

D/C/F/TAF achieved high virologic response rates that were overall noninferior to the control D/C+F/TDF, as well as favorable bone and renal outcomes that were consistent across age, gender, and race subgroups in phase 3 AMBER trial.

Posthoc analysis of the EMERALD trial reveal the combination regimen of D/C/F/TAF performs well in HIV-positive patients across different race, gender, and age subgroups, who may have failed previous antiviral regimens.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

All doses of MK-8591 were generally well-tolerated with a limited number of reported mild/moderate adverse events.

Recent research presented at CROI 2018 finds that the risk of female HIV acquisition per sex act steadily increased through pregnancy and was highest during postpartum.

Recent research presented at CROI reveals that doxycycline is an acceptable treatment alternative for HIV-positive patients who are infected with syphilis.

Researchers discuss a new method to rapidly detect HIV time-space clusters for public health intervention at CROI 2018.

At present, multiple vaccine candidates are in various stages of research and development, including cabotegravir, which is currently in phase 3 trials, and vaccines based on broadly-neutralizing antibodies.

A recent study has found that patients with HIV are six times more likely to have schizophrenia compared with those who do not have the virus.

Hair levels are found to be the strongest independent predictor of virologic success in a recent treatment trial.

At CROI 2018, Dr. Patricia Flynn discussed the impact of ART on individuals with perinatal HIV infections, and how far the infectious disease community has come since its initial use.

Raltegravir-intensified therapy resulted in significantly faster viral load declines in HIV-infected adults and older children but did not reduce overall mortality or WHO 3/4 events compared with standard triple-drug ART.

Mental health is a critical component of ending the HIV epidemic.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Jonathan Colasanti, MD, MSPH, shares how the introduction of a Rapid Entry Program in Atlanta proved successful at improving access to HIV care and viral suppression rates.

At CROI 2018, Dr. Linda-Gail Bekker highlighted 7 controversies surrounding PrEP and provided conference attendees with enough evidence to separate fact from fiction.

The medical community has learned many lessons by looking back on the early days of the HIV/AIDS epidemic, including the value of multidisciplinary teams, the vital role of acute care clinicians, and more.

Interim results of the HOPE study reveal that the vaginal ring reduced women’s risk of acquiring HIV by more than 50%. Women in this study are also using the ring more than in previous studies.

One study takes a look at how out-of-pocket costs impede the use of pre-exposure prophylaxis in young men who have sex with men.

Dr. Meg Watson from the CDC reports updated information regarding the current rates and trends of HIV diagnoses in the South at 2018 CROI.

At CROI 2018, Dr. Helen Weiss highlighted where we are in terms of meeting these goals, where the challenges are, and strategies to help prevent new infections.

In an oral abstract session at CROI 2018, Dr. Nathan Thielman stresses that understanding the interest of HIV-positive treatment-experienced individuals in new antiretroviral therapies may help inform their development and uptake.